Browse more peptide research, methods and limitations.
iGlarLixi showed differential efficacy vs IDegAsp based on baseline β-cell function, with greater benefits in patients with more preserved insulin secretion capacity.
Gu, Weijun; Wu, Xiaohong; Zhang, Minlu; Wang, Xinyi; Du, Qin; Kang, Lei; Lauand, Felipe; Alvarez, Agustina; Mu, Yiming ·
MOTS-c treatment improved intrinsic muscle mitochondrial bioenergetic capacity and energy production efficiency, with potential therapeutic applications for aging and metabolic disease.
Gudiksen, Anders; Hansen, Camilla Collin; van der Stede, Thibaux; Daugaard, Amalie Hertz; Schmidt, Josefine H; Ringholm, Stine; Merimi, Manal; Al-Obaidi, Fatima Raad; Kristoffersen, Amanda Takamiya; Zole, Egija; Regenberg, Birgitte; Kjøbsted, Rasmus; Wojtaszewski, Jørgen; Hellsten, Ylva; Pilegaard, Henriette ·
Peptide-modified nanoparticles acquired ApoE-enriched protein coronas that enhanced BBB transcytosis through receptor-mediated transport, improving brain drug delivery.
Guerrero, Simón; Hassan, Natalia; Salas-Huenuleo, Edison; Moglia, Italo; Prades, Roger; Massa, Solange; Teixido, Meritxell; Guzman, Fanny; Giralt, Ernest; Albericio, Fernando; de Oliveira, Eliandre; Araya, Eyleen; Kogan, Marcelo J ·
GLP-1 RA use was not associated with increased risk of colon cancer in adults with type 2 diabetes.
Guo, Man; Liu, Yong; Zeng, Yan; Chen, Jiao; Zeng, Chen; Huang, Lin-Lin; Wang, Ji-Ying; Wu, Yang-Hao-Tian; Wu, Qi; Teng, Fang-Yuan; Xu, Yong ·
FAERS analysis revealed differential musculoskeletal AE profiles (arthralgia, myalgia, tendon disorders) across incretin drug classes, with varying signal strength for GLP-1 RAs, dual, and triple agonists.
Guo, Meixuan; Chen, Si; Dong, Huqiang; Cai, Mengyuan; Guo, Mixue; Cheng, Hongping ·
Microfluidic fabrication produced uniform, carrier-free, peptide-modified crizotinib nanoparticles with improved tumor targeting and eliminated carrier material toxicity.
Guo, Qiuyan; Lai, Luogen; Huang, Liangxiao; Liu, Yijun; Zhang, Xuan; Yang, Silan; Li, Anqi; Li, Dangchi; Xu, Shan; Zheng, Pengwu; Lv, Qiaoli; Hu, Chong; Pan, Qingshan; Zhu, Wufu ·
GLP-1 RA vs phentermine-topiramate: aHR 0.61 (95% CI 0.41-0.91) for MACCE. GLP-1 RA vs bupropion-naltrexone: aHR 0.69 (95% CI 0.47-1.00, borderline). 35,240 and 27,051 patients in comparisons.
Guo, Wenxin; Wang, Maidou; Shin, Jiwon; Li, Fan; O'Brien, Emily C; Glover, LáShauntá; Bortfeld, Kristina; Zhao, Anqi; McDevitt, Ryan; Kalapura, Cheryl; Wu, Sarah; Shibeika, Sahar; Aymes, Shannon; Porter, Michael; Grory, Brian Mac; Lusk, Jay B ·
G(RADA)4 hydrogel: 25.9 mg/L production, 70.6% recovery, 14-day acid/pepsin stability. Drug release: sulfasalazine <5% (pH 2), 70% (pH 7.2); insulin <10% (pH 2), 75% (pH 7.2) through pH-mediated nanofiber disassembly.
Guo, Yang; Deng, Yang; Huang, Wei; Song, Liang; Jia, Pengxin; Gao, Cungang; Xu, Fei; Liu, Wenshuai; Nian, Rui ·
Sublancin: 0% skin sensitization rate in GPMT (vs 100% positive control), zero irritation score across single/repeated applications on intact and abraded skin in rabbits, no effects on body weight.
Guo, Yong; Zhang, Lin; Guo, Gantong; He, Tao; Liu, Yangke; Lai, Yujiao ·
Topical CST accelerated MRSA wound healing and reduced bacterial burden through Mrgprb2-dependent mast cell activation, suppressed inflammation, and upregulated β-defensin-14 production.
Guth, Colin; Dychtenberg, Hannah; Rudolph, Erin; Pozniak, Austin; Pundir, Priyanka ·
Liraglutide over 18 days reduced total mass (p=0.04), android fat % (p=0.04), and trunk fat (p=0.04) with no lean/bone changes. C-peptide decreased (p=0.026), IGF-1 modestly increased (p=0.002). No MAFI axis changes.
Gutierrez de Piñeres, Valeria; Tamayo-Torres, Claudia S; Ramirez-Cisneros, Arantxa; Kavelidou, Marianthi; Stefanakis, Konstantinos; Mantzoros, Christos S ·
Liraglutide 3.0 mg reduced body weight, BMI, total mass, and regional mass (trunk, hip, extremities) over 35 days. Absolute fat-free and lean mass decreased slightly, but relative percentages remained stable.
Gutierrez de Piñeres, Valeria; Ramirez-Cisneros, Arantxa; Tamayo-Torres, Claudia S; Angelidi, Angeliki M; Kavelidou, Marianthi; Stefanakis, Konstantinos; Mantzoros, Christos S ·
CIGB-552 demonstrated significant antitumor activity in vivo, with IV administration providing optimal pharmacokinetics and superior efficacy over other routes, supported by acceptable safety profiling.
Gómez Hernández, Nivaldo Angel; Martínez Durán, Luis Miguel; Milian, Héctor Santana; Garay Pérez, Hilda Elisa; Etchegoyen Amoros, Ana Yanci; Arguellez, Brizaida Oliva; Velazco, Lizet Aldana; Velazco, Jorge Castro; Rico, Ania Cabrales; Lemos, Mariana Machado; Fernández Massó, Julio Raúl ·
Vrdg183 from P. verdolaga inhibits mammalian voltage-gated sodium channels with pharmacological potential for pain and neurological applications.
Gómez-Restrepo, Alejandro; Rojas-Palomino, Jessica; Salinas-Restrepo, Cristian; Segura, César; Saurith-Coronell, Oscar A; Márquez-Brazón, Edgar A; Giraldo, Marco A; Calderón, Juan C ·
Four dermaseptin derivatives (K4K20S4, K4S4(1-16), B2, K3K4B2) showed MICs 6.25-25 μg/mL and MBCs 12.5-50 μg/mL against MDR K. pneumoniae and S. epidermidis, with concentration-dependent cytotoxicity.
Haddad, Houda; Al-Rashidi, Reyadh R; Loghmari, Ahmed; Sahtout, Wissal; Boukadida, Raja; Dahmene, Rihem; Ettouil, Emeny; Othman, Houcemeddine; Ouahchi, Ines; Zaϊri, Amira ·
Compound 12 showed low Gαq/potent β-arrestin activity at AT1R, enhanced left ventricular ejection fraction with limited pressor response in normotensive rats, and accessed a unique deep allosteric pocket in molecular modeling.
Hadjadj, Margot; Hassanzadeh, Malihe; Martel, Justin; Roy, Marie-Frédérique; Giguère, Hugo; Murza, Alexandre; Holleran, Brian J; Namkung, Yoon; Froehlich, Ulrike; Leduc, Richard; Auger-Messier, Mannix; Laporte, Stéphane A; Boudreault, Pierre-Luc ·
51 out of 150 cyanobacterial cyclic peptides contained cis-prolyl amide bonds, a functionally significant conformation that is frequently unreported in the literature.
Haedar, Jabal Rahmat; Khan, Abujunaid Habib; Coxon, Christopher R; Phan, Chin-Soon ·
Rimegepant significantly reduced rectal gas, urgency, and pain sensations during 24/36 mmHg distension (all p<0.05) and decreased rectal compliance, despite not significantly reducing daily abdominal pain in 24 IBS patients.
Halawi, Houssam; Matar, Ayah; Wang, Iris; Jencks, Kara J; Busciglio, Irene; Eckert, Deborah; Harmsen, William S; Camilleri, Michael ·
AlphaFold2-based cyclic peptide design achieved similar or better calculated interaction scores than known PPI binders, with well-balanced dual binding and applicability to bifunctional protein degradation targeting.
Halbwedl, Niklas; Zacharias, Martin ·
GLP-1 RAs are now the fourth therapeutic pillar for CKD in T2D, with expert guidance on integrating them with RAAS inhibitors, SGLT2i, and finerenone based on individual patient factors.
Halimi, Jean-Michel; Fauchier, Laurent; Karras, Alexandre; Amouyal, Chloé; Eladari, Dominique; Rossignol, Patrick; Choukroun, Gabriel; Zaoui, Philippe; Girerd, Nicolas; Hadjadj, Samy ·
Dual air-water + silicone oil-water interfacial stress, not either alone, drives liraglutide fibrillation in PFS. First-ever SRS visualization of peptide adsorption on silicone oil at sub-micrometer resolution. NMR showed aggregation without specific binding.
Hamada, Naomi; Cutts, Aaron; Song, Jing; Hu, Guangli; Fu, Dan; Wuelfing, W Peter; Su, Yongchao; Ling, Jing ·
Orforglipron: dose-dependent weight loss up to 12 kg (non-diabetic) and 6 kg (diabetic), HbA1c -1.29%, significant BMI/waist reductions, dose-dependent GI AEs, no pancreatitis signal across 5 RCTs (n=6,140).
Hammad, Noha; Ramadan, Aya M; Nazmy, Ahmed; Elazab, Ahmed; Abdelaziz, Ahmed ·
Gp-AMP1: broad-spectrum bactericidal via membrane disruption + ROS induction; thermal/pH stable; low cytotoxicity/hemolysis; inhibited pork spoilage bacteria.
Han, Guanghui; Chen, Hao; Zhuo, Lianhong; Yu, Haoyu; Wu, Ning; Wang, Minxiao; Song, Jiangning; Li, Chaolun ·
GLP-1/GIP therapies cause 15-45% lean mass loss proportional to total weight reduction, with potential cardiovascular implications through sarcopenia-CVD bidirectional relationship, particularly in elderly and heart failure populations.
Haner Wasserstein, David; Whitford, Tobias; Whiteson, Harris Z; Frishman, William H ·
Combined GIP+GLP-1+GLP-2 infusion during IIGI suppressed β-CTX-I (bone resorption) comparably to OGTT. Individual GIP, GLP-1 had partial effects. PINP (formation) decreased with OGTT/saline/GLP-2 but not with GIP/GLP-1/triple infusion.
Hansen, Josefine V; Mathiesen, David S; Christensen, Mikkel B; Jørgensen, Niklas R; Helsted, Mads M; Bagger, Jonatan I; Holst, Jens J; Vilsbøll, Tina; Knop, Filip K; Lund, Asger B ·
SGLT2i vs GLP-1RA: DKA IR 4.37 vs 3.13 per 1,000 person-years; HR 1.40 (95% CI 1.16-1.68); NNH 813; consistent across age, sex, BMI, frailty, CVD, retinopathy, metformin, and insulin subgroups.
Hansrivijit, Panupong; Patorno, Elisabetta; Tesfaye, Helen; Wexler, Deborah J; Paik, Julie M ·
Silymarin@SCP-Gal nanocarriers: 42.28 nm, 75.54% encapsulation, hepatocyte-targeted via galactosyl receptor, significantly reduced ethanol-induced cytotoxicity and oxidative stress in LO2 cells.
Hao, Sijia; Wang, Yuxiao; Lv, Yueqi; Liu, Kangjing; Tan, Mingqian ·
Semaglutide reduced preferences for sweet/non-sweet carbohydrates and non-sweet fats (especially rice, noodles, high-fat snacks) while protein and fiber preferences were unchanged. Non-GLP-1 group showed no preference changes.
Hara, Tomoyuki; Fujishima, Yuya; Kimura, Yu; Fujii, Kohei; Kawachi, Yusuke; Nagao, Hirofumi; Obata, Yoshinari; Fukuda, Shiro; Nagai, Naoko; Nishizawa, Hitoshi; Shimomura, Iichiro ·
P-15L was superior to autograft: fusion 84.3% vs 58.5%, composite clinical success 55.5% vs 37.5% (p=0.002 superiority), with similar device-related SAE rates at 24 months.
Harrop, James S; O'Toole, John E; Steinmetz, Michael P; Sasso, Rick C; Chaput, Christopher D; Strenge, K Brandon; Maislin, Greg; Mullin, Jeffrey P; Freeman, Thomas B; Guanciale, Anthony; Lantner, Howard; Janssen, Michael E; Schwartz, David G; Small, John M; Hsu, Wellington K; Arnold, Paul M ·
P-15L superior time-to-fusion: HR 1.87 (95% CI 1.47-2.38, p<0.0001). Fusion rates: 6mo 57.6% vs 26.9%; 12mo 68.8% vs 41.5%; 24mo 81.1% vs 54.9%. ~59% had pseudoarthrosis risk factors. Both groups improved in VAS and SF-12.
Harrop, James S; Steinmetz, Michael P; O'Toole, John E; Chaput, Christopher D; Sasso, Rick C; Strenge, K Brandon; Maislin, Greg; Mullin, Jeffrey P; Freeman, Thomas B; Guanciale, Anthony; Lantner, Howard; Janssen, Michael E; Schwartz, David G; Small, John M; Hsu, Wellington K; Arnold, Paul M ·
SGLT2i vs GLP-1 RA: kidney failure HR trending lower for SGLT2i (0.89); MACE higher with SGLT2i (HR 1.14). KFRE modified effects: GLP-1 RA better at moderate risk; SGLT2i better at high kidney failure risk.
Hartsell, Sydney E; Wei, Guo; Singh, Ravinder; Throolin, Michael; Nevers, McKenna R; Sarwal, Amara; Derington, Catherine G; Curtis, Christa; Boucher, Robert E; Shen, Jincheng; Drakos, Stavros; Greene, Tom; Beddhu, Srinivasan ·
AMPs face clinical barriers (PK instability, poor specificity, immunogenicity) addressable through ML/DL-guided design, MD simulations, and emerging quantum computing, with an urgent need to integrate computational and experimental pipelines.
Haryini, Sree; Manku, Komalpreet Kaur; Deshkar, Aishwari; Doss C, George Priya ·
GLP-1 use associated with lower post-operative AF (14% vs 22%, p=0.02) in CABG patients. No significant difference in all-cause mortality or MACCE. Similar overall length of stay.
Hasan, Irsa; Bessette, Lily G; Jacquemyn, Xander; Wang, Yisi; Subramaniam, Kathir; Hasan, Zain; Thoma, Floyd; Ogami, Takuya; Bonatti, Johannes; Kaczorowski, David; Chu, Danny; Serna-Gallegos, Derek; Sultan, Ibrahim ·
NCB semaglutide: 6.9% weight loss at 12 weeks, 13.3% at 24 weeks; 74.7% on 0.5 mg dose; any AEs 59.4%; major AEs 9.9%; 14.6% lost to follow-up; 1 death.
Hasan, Md Rakibul; Shil, Kishore Kumar; Shahed-Morshed, Md ·
Direct W/O emulsion-based PLGA microneedle fabrication maintained peptide bioactivity during manufacturing and storage, achieved high loading and uniform geometry, and demonstrated sustained 72-hour transdermal release in vivo.
Hasan, Reaid; Guo, Yuhan; Zhao, Zhen; Li, Yongren; Mamani, Umar-Farouk; Cheng, Kun ·
EM_4: MIC 2.5-20 μM against susceptible and XDR S. aureus/A. baumannii; MBC 5-20 μM; antibiofilm 40-80 μM; 3.2% hemolysis; thermostable and salt-stable; membrane-disrupting mechanism.
Hasannejad-Asl, Behnam; Bagheri, Kamran Pooshang; Bandehpour, Mojgan; Bolhassani, Azam; Hashemi, Ali; Pooresmaeil, Farkhondeh; Kazemi, Bahram ·
GLP-1 RA MACE reduction: Asian HR 0.73 (p<0.001); White HR 0.86 (p<0.001); Black HR 0.88 (p=0.34). Asian vs White RHR 0.84 (p=0.027), indicating significantly greater benefit in Asians.
Hasebe, Masashi; Su, Chen-Yang; Kamido, Hisashi; Yabe, Daisuke; Yoshiji, Satoshi ·
Integrated electrophysiological scoring of AMP activity on IM + smooth-type LPS OM models predicted MIC with R=0.99, whereas individual membrane models alone did not reliably predict antimicrobial potency.
Hashimoto, Wakana; Takeuchi, Nanami; Hagiri, Yuki; Sato, Mana; Kawano, Ryuji ·
Lipidated IL-22: 20% weight loss monotherapy, 40% with GLP-1 RA; <50% lean mass loss vs GLP-1 RA/caloric restriction; doubled fecal energy loss; increased PYY; normalized glucose independently of food intake.
Hass, Daniela; Madsen, Andreas N; da Silva-Buttkus, Patricia; Kjølbye, Anne Louise; Støy, Sidsel; Nøhr-Meldgaard, Jacob; Sandahl, Thomas D; Hrabě de Angelis, Martin; Jorgensen, Rasmus; Rohm, Maria; van de Bunt, Martijn ·
Fixed-ratio GLP-1/insulin combinations improve glycemic control with weight neutrality or loss and less hypoglycemia vs insulin intensification, while reducing treatment complexity.
Hassanein, Mohamed; Alessa, Thamer; Hafidh, Khadija A; Alzubaidi, Lamya; Jallo, Mahir; Al Slail, Fatma; Elbadawi, Hussein; Malik, Rayaz A ·
GLP-1 RA vs DPP-4i: stroke aHRR 0.69 (0.53-0.91). SGLT2i vs DPP-4i: stroke aHRR 0.80 (0.64-1.01, NS). Both GLP-1 RA and SGLT2i reduced mortality vs DPP-4i. No MI differences. GLP-1 vs SGLT2i: no significant differences.
Hastrup, Sidsel; Hedegaard, Jakob N; Andersen, Grethe; Osler, Merete; Rungby, Jørgen; Johnsen, Søren Paaske ·
Up to 40% of transplant recipients are obese, with post-transplant weight gain worsening outcomes. GLP-1/GIP drugs are promising but lack dedicated transplant RCT data for safety and efficacy.
Haugen, Christine E; Orandi, Babak J ·
Oral semaglutide (0.12 mg/kg/day) reduced liver fibrosis via SIRT1 activation and TGF-β/Smad downregulation, with reduced α-SMA, improved liver function, and mitigated oxidative stress in TAA-treated mice.
Hawary, Omnia A; Wadie, Walaa; El-Said, Yasmin A M; Hassan, Omnia F ·
scFv-p16-S413-doxorubicin AFDC: p16 expression-dependent selectivity, stronger cytotoxicity against p16-high (HeLa, BT-549) vs p16-low cells, target-dependent internalization, and marked viability reduction in TNBC organoids.
He, Hui; Chen, Xiaoling; Chen, Yueqiu; Li, Qingpeng; Yang, Fan; Zhou, Lin ·
Trx-SPRR2A: 7.18 mg/L yield, 94.5% purity, 5 correct disulfide bonds. Antibacterial: selective Gram-positive. Anticancer: MCF-7 selective at acidic pH. Mechanism: membrane disruption (both) + apoptosis (cancer).
He, Pinlong; Liu, Hongrui; Yuan, Junyi; Gao, Hui; Li, Bin-Chun; Stauber, Roland H; Li, Bozhao; Ding, Guo-Bin ·
FAM237B: conserved micropeptide in AgRP/NPY neurons; expression rises with fasting, suppressed by insulin (PI3K-dependent), and upregulated by pro-inflammatory stimuli (LPS, IL-6, TNF-α).
He, Wenyuan; McIlwraith, Emma K; Belsham, Denise D ·
Semaglutide vs SGLT2i: NAION incidence 123 vs 67/100,000 PY; HR 2.33 (95% CI 1.54-3.54, p<0.001); absolute risk 0.29% vs 0.13%; overlap-weighted analysis of 102,361 veterans.
Heberer, Kent; Bress, Adam P; Cogill, Steven; Maldonado, Ana I; Kim, Sun H; Nallamshetty, Shriram; Chen, Ying Q; Shih, Mei-Chiung; Lynch, Julie A; Lee, Jennifer S ·
RYGB vs OAGB: early-phase GLP-1 AUC 31% higher at 6 months (p=0.030); peak GLP-1 ~32% higher (p<0.05); total GLP-1 AUC increase: RYGB 330% vs OAGB 259%; greater hunger reduction with RYGB; similar weight loss (~25%).
Heinonen, S; Karppinen, J E; Saarinen, T; Groop, P-H; Juuti, A; Holst, J J; Pietiläinen, K H ·
T-cell response in 19/20 patients (95%) at end of treatment; persistence in 16/19 (84%) at 6 months with increasing intensity; both CD4+ and CD8+ activation; manageable injection-site AEs; no treatment-related SAEs.
Heitmann, Jonas S; Maringer, Yacine; Jung, Susanne; Wacker, Marcel; Hackenbruch, Christopher; Polster, Mark; Marconato, Maddalena; Nelde, Annika; Bauer, Jens; Zwick, Melissa; Baur, Anna-Sophia; Metzger, Ariane; Krolla, Christopher; Andrieux, Geoffroy; Köhler, Natalie; Boerries, Melanie; Denk, Monika; Zieschang, Lisa; Kammer, Christine; Hoenisch-Gravel, Naomi; Richter, Marion; Oezbek, Melek Tutku; Wirths, Stefan; Dengler, Anna; Dubbelaar, Marissa L; Pumptow, Marina; Martus, Peter; Brüggemann, Monika; Rammensee, Hans-Georg; Salih, Helmut R; Walz, Juliane S ·
GLP-1 RAs have compelling neuroprotective rationale for ALS (anti-inflammatory, mitochondrial, anti-excitotoxic) but their weight loss and lean mass reduction effects may worsen ALS prognosis, where higher BMI/weight maintenance is protective.
Helal, Mohamed Mohsen; Almosilhy, Nereen A; Abo-Elnour, Dina Essam; Jaffal, Rana Suhail Younis; Allam, Eman Gomaa; Almosilhy, Mohammed A; Batarseh, Suhel F; Meshref, Mostafa ·